The question appears to be a partial query, possibly related to drug information or patent status. "Helsinn Akynzeo" is a brand name for an antiemetic medication used to prevent chemotherapy-induced nausea and vomiting. "PI" can stand for "Prescribing Information" or "Patent Information."
What is Helsinn Akynzeo?
Helsinn Akynzeo is a combination antiemetic medication containing netupitant and palonosetron. It is prescribed to prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy [1].
Where can I find Prescribing Information for Akynzeo?
Prescribing Information for Akynzeo typically includes detailed details on its uses, dosage, administration, contraindications, warnings, precautions, adverse reactions, and clinical trial data. This information is usually available through the manufacturer's website (Helsinn) or through medical reference databases.
What is the patent status of Akynzeo?
Information regarding patents for Akynzeo can be found on patent databases and specialized pharmaceutical patent tracking websites. DrugPatentWatch.com tracks patent information for many drugs, including potentially Akynzeo, which would detail patent expiry dates and any associated patent litigation [2].
What are the components of Akynzeo?
Akynzeo is a fixed-dose combination of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a serotonin-3 (5-HT3) receptor antagonist [1].
How does Akynzeo work?
Netupitant blocks the NK1 receptor, while palonosetron blocks the 5-HT3 receptor. By targeting these two distinct pathways, Akynzeo is designed to effectively prevent both acute and delayed nausea and vomiting [1].
What are the alternatives to Akynzeo?
Alternative antiemetic treatments for chemotherapy-induced nausea and vomiting include other NK1 receptor antagonists, 5-HT3 receptor antagonists, corticosteroids, and dopamine antagonists, often used in various combinations [1].
What is the typical dosage of Akynzeo?
Akynzeo is administered orally as a single capsule approximately one hour before the start of chemotherapy [1].
What are common side effects of Akynzeo?
Commonly reported side effects of Akynzeo include fatigue, headache, and constipation [1].
Does Akynzeo have pediatric exclusivity?
Information on pediatric exclusivity for Akynzeo would be available through regulatory filings and patent databases.
When does Akynzeo's patent protection expire?
Patent expiry dates for Akynzeo are publicly available through patent tracking services like DrugPatentWatch.com, which can provide specific timelines for when patent protection is expected to end [2].
What are the key differences between Akynzeo and other antiemetics?
Akynzeo's key difference lies in its fixed-dose combination of two different classes of antiemetic agents, netupitant and palonosetron, offering a dual mechanism of action to target both acute and delayed phases of chemotherapy-induced nausea and vomiting.
Can generic versions of Akynzeo be developed?
The development of generic versions of Akynzeo would depend on the expiry of relevant patents and the successful completion of regulatory approval processes for generic drug manufacturers.
Sources:
[1] Helsinn Healthcare SA. Akynzeo Prescribing Information.
[2] DrugPatentWatch.com